“Increasing Diagnosis and Availability of Targeted Therapies”
- One prominent trend in the neurotrophic keratitis treatment market is the increasing rate of diagnosis coupled with the launch of targeted biologics such as cenegermin (Oxervate).
- As clinical awareness grows among ophthalmologists, especially regarding early-stage neurotrophic keratitis, more patients are being diagnosed before reaching advanced corneal damage
- For instance, novel treatments such as Oxervate by Dompé Pharma have demonstrated strong efficacy in restoring corneal integrity, providing a much-needed solution for a previously underserved patient population.
- This trend is significantly transforming NK management, enabling earlier intervention, reducing the need for surgical treatment, and improving patient outcomes
- The neurotrophic keratitis treatment market is expected to witness sustained growth, supported by increased diagnostic capabilities, ongoing innovation in regenerative ophthalmology, and a focus on improving quality of life for patients with rare ocular diseases
